NCT06884514View on ClinicalTrials.gov

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
Healthy
Interventions
DRUG

Psilocybin

A moderate dose of 20 mg psilocybin will be administered.

DRUG

3,4-Methylenedioxymethamphetamine

A moderate dose of 100 mg MDMA will be administered.

DRUG

Psilocybin placebo

Mannitol capsules instead of capsules containing psilocybin.

DRUG

3,4-Methylenedioxymethamphetamine placebo

Mannitol capsules instead of capsules containing MDMA.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER